Patents by Inventor Yasuko Tomono

Yasuko Tomono has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220111063
    Abstract: One purpose of the present invention aims to provide a novel drug delivery means for targeting neovascularity. Another purpose of the invention is to provide a novel drug delivery means for targeting hyperpermeable vasculature. Still another purpose of the invention is to provide a method and a detection reagent for treatment or diagnosis of various diseases including malignant tumors. The present conjugate of a drug and an anti-HMGB1 antibody or an antigen-binding fragment thereof is administered to a subject and incorporated into proangiogenic or hyperpermeable vascular endothelial cells to deliver the drug to the cells. In addition, the conjugate is used to provide a method and a detection reagent for treatment or diagnosis of various diseases including malignant tumors.
    Type: Application
    Filed: December 17, 2020
    Publication date: April 14, 2022
    Inventors: Masahiro NISHIBORI, Shuji MORI, Shangze GAO, Masakiyo SAKAGUCHI, Yasuko TOMONO
  • Publication number: 20210198382
    Abstract: Provided is a more effective anti-inflammatory agent having less side effects as compared to NSAIDs and steroidal anti-inflammatory agents. A therapeutic agent for inflammatory diseases containing as an active ingredient an anti-4-HNE antibody, which inhibits 4-HNE, has been found to have ameliorating effects on the expressions of various inflammation markers involved in cerebral infarction and cerebral ischemia-reperfusion, and has also been found to have life-prolonging and life-saving effects in sepsis model animals. The anti-4-HNE antibody shows remarkable efficacy even on inflammatory diseases on which existing anti-inflammatory drugs, such as NSAIDs and steroidal anti-inflammatory agents, have hitherto not shown effects.
    Type: Application
    Filed: May 23, 2019
    Publication date: July 1, 2021
    Inventors: Masahiro NISHIBORI, Shuji MORI, Yuta MORIOKA, Hidenori WAKE, Yasuko TOMONO
  • Publication number: 20200163938
    Abstract: The present invention provides a pharmaceutical composition comprising an iron chelating agent exhibiting antitumor activity, antimicrobial activity, and/or antivirus activity and having reduced side effects. Specifically, the present invention provides a pharmaceutical composition for use in treatment of cancer or infectious disease, comprising an iron chelating agent that selectively binds to biologically unstable iron, rather than to transferrin-bound iron.
    Type: Application
    Filed: May 10, 2018
    Publication date: May 28, 2020
    Applicant: Disease Adsorption System Technologies Co., Ltd.
    Inventors: Yuzo NISHIDA, Toshiaki OHARA, Kazuhiro OMORI, Yasuko TOMONO
  • Publication number: 20120183556
    Abstract: The objective of the present invention is to provide an agent which is useful for suppressing actual atherosclerosis and has few side-effects. The suppressant for atherosclerosis according to the present invention is characterized in comprising an anti-HMGB1 monoclonal antibody binding to C-tail of HMGB1 as an active component.
    Type: Application
    Filed: September 27, 2010
    Publication date: July 19, 2012
    Inventors: Masahiro Nishibori, Hideo Takahashi, Shuji Mori, Keyue Liu, Yasuko Tomono
  • Patent number: 8071098
    Abstract: An objective of the present invention is to provide a cerebral vasospasm inhibitor which is effective on cerebral vasospasm occurring after subarachnoid hemorrhage and has few side-effects. The cerebral vasospasm inhibitor of the invention is characterized in containing an anti-HMGB1 monoclonal antibody as an active ingredient.
    Type: Grant
    Filed: May 18, 2007
    Date of Patent: December 6, 2011
    Assignee: National University Corporation Okayama University
    Inventors: Masahiro Nishibori, Shuji Mori, Hideo Takahashi, Yasuko Tomono, Isao Date, Shigeki Ono
  • Publication number: 20100172909
    Abstract: The objective to be solved by the present invention is to provide a method for effectively suppressing cerebral edema. The method for suppressing cerebral edema according to the present invention is characterized in comprising a step of administering an anti-HMGB 1 antibody recognizing 208EEEDDDDE215 (SEQ ID NO:1) as an HMGB1 epitope.
    Type: Application
    Filed: January 4, 2010
    Publication date: July 8, 2010
    Inventors: Masahiro Nishibori, Shuji Mori, Hideo Takahashi, Yasuko Tomono, Naoto Adachi, Keyue Liu
  • Publication number: 20090252739
    Abstract: An objective of the present invention is to provide a suppressant for cerebral infarction occurred after long-term ischemia associated with actual cerebral infarction, and has fewer side effects. The cerebral infarction suppressant of the present invention is characterized in comprising an anti-HMGB1 monoclonal antibody as an active ingredient.
    Type: Application
    Filed: October 13, 2006
    Publication date: October 8, 2009
    Inventors: Masahiro Nishibori, Shuji Mori, Hideo Takahashi, Yasuko Tomono, Naoto Adachi, Keyue Liu
  • Publication number: 20090175878
    Abstract: An objective of the present invention is to provide a cerebral vasospasm inhibitor which is effective on cerebral vasospasm occurring after subarachnoid hemorrhage and has few side-effects. The cerebral vasospasm inhibitor of the invention is characterized in containing an anti-HMGB1 monoclonal antibody as an active ingredient.
    Type: Application
    Filed: May 18, 2007
    Publication date: July 9, 2009
    Inventors: Masahiro Nishibori, Shuji Mori, Hideo Takahashi, Yasuko Tomono, Isao Date, Shigeki Ono